Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
about
Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma.Immunotherapy of multiple myeloma: the start of a long and tortuous journey.Maintenance therapy in multiple myeloma.High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years.Targeted treatments to improve stem cell outcome: old and new drugs.Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in OncologyPoor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation: a single center experience.New therapies in multiple myeloma.Review of thalidomide in the treatment of newly diagnosed multiple myeloma.Role of thalidomide in previously untreated patients with multiple myeloma.In pursuit of the allo-immune response in multiple myeloma: where do we go from here?Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.Efficacy and safety of busulfan-based conditioning regimens for multiple myelomaMultiple myeloma maintenance therapy: a review of the pharmacologic treatment.Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients.High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease.
P2860
Q33404348-521D022D-013E-4995-A2C2-7A1187F0E27DQ34034447-61548264-8E81-4E93-AB0E-664CD472604EQ36689152-2B805362-4ACB-4835-B950-12996C3DE0A3Q36754178-181655D6-3ABA-4ECA-8661-FCE7AF9D123BQ36902837-83437C47-3BF7-4A67-91C1-66855E906AF2Q36927960-A547BF11-6DB0-4F4D-8B1F-222B14025F95Q36963203-23128F82-7C07-4E39-B748-A1DE8E896C24Q36966074-95EC5EB8-33DB-4D04-8AD6-746DD5661E58Q36986576-D9DBE552-D8C1-42DC-BFEF-AC3D19DF7C7AQ37160347-AA394919-B00D-4A6C-AA4A-184A13CD60E8Q37300004-C76CEFD6-F321-4893-BEE4-0E3C84C777DAQ37349835-6D7A37DB-08FC-403B-8544-965771FBB6F9Q37761370-70CFF17A-6AB7-4F07-94F3-50ACBA408FFBQ38102892-2020EA6D-7ED7-496E-825C-141E9B9F96F3Q38176293-5BF932CF-D5B7-4FA4-8518-73BE4DE07D79Q45064253-B7EB27F3-34B9-4B41-A70B-6031B1A7C2A9Q53470095-352F3EFB-A749-4B4F-AAE5-6AECBB5BE1BA
P2860
Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Maintenance therapy with thali ...... antation for multiple myeloma.
@ast
Maintenance therapy with thali ...... antation for multiple myeloma.
@en
type
label
Maintenance therapy with thali ...... antation for multiple myeloma.
@ast
Maintenance therapy with thali ...... antation for multiple myeloma.
@en
prefLabel
Maintenance therapy with thali ...... antation for multiple myeloma.
@ast
Maintenance therapy with thali ...... antation for multiple myeloma.
@en
P2093
P356
P1433
P1476
Maintenance therapy with thali ...... antation for multiple myeloma.
@en
P2093
Amelia A Langston
Brett T Brinker
Edmund K Waller
Istvan Redei
Leonard T Heffner
Traci Leong
P304
P356
10.1002/CNCR.21852
P407
P50
P577
2006-05-01T00:00:00Z